

Keunchil Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4716019/publications.pdf>

Version: 2024-02-01

565
papers

42,231
citations

5782

84
h-index

3595

187
g-index

578
all docs

578
docs citations

578
times ranked

36090
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. <i>Cancer Research and Treatment</i> , 2023, 55, 83-93. | 1.3 | 2 |
| 2 | Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. <i>Cancer Research and Treatment</i> , 2022, 54, 150-156. | 1.3 | 0 |
| 3 | Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 21-33. | 1.1 | 12 |
| 4 | First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308. | 0.5 | 173 |
| 5 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2022, 28, 1117-1126. | 3.2 | 52 |
| 6 | ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 265. | 1.2 | 2 |
| 7 | Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review. <i>Clinical Lung Cancer</i> , 2022, 23, 195-207. | 1.1 | 22 |
| 8 | Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 415-425. | 0.4 | 9 |
| 9 | Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor. <i>Oncology</i> , 2022, 100, 228-237. | 0.9 | 2 |
| 10 | Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001. <i>Journal of Thoracic Oncology</i> , 2022, 17, 768-778. | 0.5 | 20 |
| 11 | A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. <i>Clinical Lung Cancer</i> , 2022, 23, 300-310. | 1.1 | 12 |
| 12 | Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. <i>Clinical Lung Cancer</i> , 2022, 23, 320-332. | 1.1 | 5 |
| 13 | Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. <i>Current Oncology</i> , 2022, 29, 2154-2164. | 0.9 | 16 |
| 14 | Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928. | 0.8 | 94 |
| 15 | ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. <i>Lancet Oncology</i> , The, 2022, 23, 463-464. | 5.1 | 3 |
| 16 | Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 900-908. | 0.5 | 23 |
| 17 | Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2022, 11, 2944-2956. | 1.3 | 24 |
| 18 | Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. <i>Frontiers in Oncology</i> , 2022, 12, 834704. | 1.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head&neck cancer. <i>Cancer Medicine</i> , 2022, 11, 2550-2560. | 1.3 | 25 |
| 20 | Structure-based prediction of neoantigens paired with T cell receptors on pre-existing CD8+ tumor-infiltrating lymphocytes.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14583-e14583. | 0.8 | 0 |
| 21 | Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4312-4321. | 3.2 | 7 |
| 22 | Phase III study of selpercatinib versus chemotherapy ±pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 763-773. | 1.1 | 30 |
| 23 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non&small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 992-1002. | 3.2 | 36 |
| 24 | Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2021, 16, 140-150. | 0.5 | 95 |
| 25 | Olmotinib in T790M&positive non&small cell lung cancer after failure of first&line epidermal growth factor receptor&tyrosine kinase inhibitor therapy: A global, phase 2 study. <i>Cancer</i> , 2021, 127, 1407-1416. | 2.0 | 17 |
| 26 | Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. <i>Annals of Palliative Medicine</i> , 2021, 10, 1589-1598. | 0.5 | 5 |
| 27 | Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 878-888. | 1.3 | 4 |
| 28 | Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non&small cell lung cancer. <i>European Journal of Immunology</i> , 2021, 51, 956-964. | 1.6 | 15 |
| 29 | Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850. | 1.0 | 2 |
| 30 | Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S217-S224. | 0.7 | 6 |
| 31 | Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021, 64, 271-281. | 0.5 | 8 |
| 32 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359. | 0.8 | 147 |
| 33 | Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. <i>Lung Cancer</i> , 2021, 154, 92-98. | 0.9 | 3 |
| 34 | High concordance of actionable genomic alterations identified between circulating tumor DNA&based and tissue&based next&generation sequencing testing in advanced non&small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028. | 2.0 | 37 |
| 35 | KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8512-8512. | 0.8 | 13 |
| 36 | Updated overall efficacy and safety of selpercatinib in patients (pts) with <i>RET</i> fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9065-9065. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG) Tj ETQq1 1 0.784314 rgBT ₂ /Overlo | 0.8 | 1 |
| 38 | Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. Lung Cancer, 2021, 155, 127-135. | 0.9 | 6 |
| 39 | Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2021, 39, 9032-9032. | 0.8 | 1 |
| 40 | The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 8562-8562. | 0.8 | 5 |
| 41 | The NHance [®] Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. Biomedicines, 2021, 9, 665. | 1.4 | 2 |
| 42 | Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. European Journal of Endocrinology, 2021, 184, 837-845. | 1.9 | 16 |
| 43 | Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-“Small-Cell Lung Cancer (PACIFIC). Clinical Lung Cancer, 2021, 22, 549-561. | 1.1 | 25 |
| 44 | EGFR tyrosine kinase inhibitors for <i>EGFR</i> mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncology, 2021, 17, 2395-2408. | 1.1 | 17 |
| 45 | Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-“Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clinical Cancer Research, 2021, 27, 4160-4167. | 3.2 | 64 |
| 46 | O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial. Annals of Oncology, 2021, 32, S291. | 0.6 | 1 |
| 47 | An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-na [~] ve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. BMC Cancer, 2021, 21, 802. | 1.1 | 5 |
| 48 | Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study. Cancer Research, 2021, 81, CT163-CT163. | 0.4 | 8 |
| 49 | Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology, 2021, 39, 2327-2338. | 0.8 | 146 |
| 50 | RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5258-5271. | 3.2 | 23 |
| 51 | MO4-7 Efficacy and safety with selpercatinib in patients with RET fusion+ NSCLC: Analysis by last prior systemic therapy. Annals of Oncology, 2021, 32, S297. | 0.6 | 0 |
| 52 | O13-3 Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from VISION cohort A. Annals of Oncology, 2021, 32, S290. | 0.6 | 0 |
| 53 | Afatinib in EGFR TKI-Na [~] ve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology, 2021, 11, 709877. | 1.3 | 6 |
| 54 | SY4-2 Immune checkpoint inhibition in malignant pleural mesothelioma and thymic epithelial tumors. Annals of Oncology, 2021, 32, S249. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402. | 0.8 | 320 |
| 56 | Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1369-1378. | 0.5 | 31 |
| 57 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100206. | 0.6 | 3 |
| 58 | Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1351. | 3.4 | 113 |
| 59 | Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102415. | 1.7 | 16 |
| 60 | Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. <i>Translational Lung Cancer Research</i> , 2021, 10, 3865-3874. | 1.3 | 4 |
| 61 | Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. <i>European Journal of Cancer</i> , 2021, 159, 167-173. | 1.3 | 6 |
| 62 | Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4209-4220. | 1.3 | 6 |
| 63 | Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 360-368. | 1.2 | 32 |
| 64 | Real-world use of osimertinib in nonâ€“small cell lung cancer: ASTRIS study Korean subgroup analysis. <i>Current Medical Research and Opinion</i> , 2020, 36, 477-482. | 0.9 | 9 |
| 65 | Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. <i>Head and Neck</i> , 2020, 42, 924-938. | 0.9 | 20 |
| 66 | Junction Location Identifier (JuLI). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 304-318. | 1.2 | 6 |
| 67 | Osimertinib for Patients With Nonâ€“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020, 38, 488-495. | 0.8 | 233 |
| 68 | Benefit of Targeted DNA Sequencing in Advanced Nonâ€“Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190. | 1.1 | 5 |
| 69 | Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 609-617. | 0.5 | 27 |
| 70 | Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small cell lung cancer: East Asian subset of RELAY. <i>Cancer Science</i> , 2020, 111, 4510-4525. | 1.7 | 17 |
| 71 | Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199. | | 7 |
| 72 | Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?. <i>Biology</i> , 2020, 9, 326. | 1.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. <i>Lung Cancer</i> , 2020, 147, 137-142. | 0.9 | 37 |
| 74 | The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1749-1758. | 1.3 | 14 |
| 75 | A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756. | 1.3 | 36 |
| 76 | Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. <i>Scientific Reports</i> , 2020, 10, 13231. | 1.6 | 11 |
| 77 | Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. <i>BMC Cancer</i> , 2020, 20, 727. | 1.1 | 17 |
| 78 | First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679. | 1.4 | 9 |
| 79 | Evaluating entrectinib as a treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1935-1942. | 0.9 | 8 |
| 80 | Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1758-1766. | 0.5 | 60 |
| 81 | KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217. | 13.9 | 1,049 |
| 82 | Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824. | 13.9 | 505 |
| 83 | Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1019-1026. | 0.6 | 1 |
| 84 | Integrative genomic analysis of salivary duct carcinoma. <i>Scientific Reports</i> , 2020, 10, 14995. | 1.6 | 12 |
| 85 | Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3796-3803. | 0.6 | 19 |
| 86 | Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVD). <i>European Journal of Cancer</i> , 2020, 137, 272-284. | 1.3 | 86 |
| 87 | Regulatory (FoxP3+) T cells and TGF- β^2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18994. | 1.6 | 52 |
| 88 | Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping. <i>In Vivo</i> , 2020, 34, 1399-1406. | 0.6 | 10 |
| 89 | Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020, 11, 2285. | 5.8 | 565 |
| 90 | Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020, 132, 150-158. | 1.3 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overlock 169 8, 1132-1143. | 5.2 | 169 |
| 92 | Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer, 2020, 146, 23-29. | 0.9 | 87 |
| 93 | Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery. Journal of Thoracic Disease, 2020, 12, 2602-2613. | 0.6 | 6 |
| 94 | MDSC subtypes and CD39 expression on CD8 ⁺ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. European Journal of Immunology, 2020, 50, 1810-1819. | 1.6 | 57 |
| 95 | Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care;) Tj ETQq1 1 0.784314 rgBT /Overlock 169 | 1.0 | 10 |
| 96 | Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Cancer, 2020, 126, 2704-2712. | 2.0 | 26 |
| 97 | Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. Cancer, 2020, 126, 4002-4012. | 2.0 | 22 |
| 98 | PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Medicine, 2020, 9, 2352-2362. | 1.3 | 29 |
| 99 | Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study. Targeted Oncology, 2020, 15, 75-84. | 1.7 | 13 |
| 100 | Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. Nature Communications, 2020, 11, 951. | 5.8 | 34 |
| 101 | Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology, 2020, 9, 1722023. | 2.1 | 37 |
| 102 | New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540. | 0.5 | 119 |
| 103 | Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. Japanese Journal of Clinical Oncology, 2020, 50, 594-601. | 0.6 | 23 |
| 104 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology, 2020, 15, 803-815. | 0.5 | 178 |
| 105 | Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC Ophthalmology, 2020, 20, 19. | 0.6 | 32 |
| 106 | Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. Respiratory Research, 2020, 21, 13. | 1.4 | 8 |
| 107 | Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature, 2020, 578, 102-111. | 13.7 | 424 |
| 108 | Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1630-1637. | 2.9 | 472 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Comprehensive molecular characterization of mitochondrial genomes in human cancers. <i>Nature Genetics</i> , 2020, 52, 342-352. | 9.4 | 256 |
| 110 | Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3584-3584. | 0.8 | 14 |
| 111 | Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9512-9512. | 0.8 | 54 |
| 112 | Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9516-9516. | 0.8 | 17 |
| 113 | Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 292-300. | 1.3 | 17 |
| 114 | <i>EGFR</i> C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with <i>EGFR</i> T790M Mutation. <i>Cancer Research and Treatment</i> , 2020, 52, 1288-1290. | 1.3 | 12 |
| 115 | Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. <i>Immune Network</i> , 2020, 20, e48. | 1.6 | 10 |
| 116 | CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES. <i>Neuro-Oncology</i> , 2020, 22, ii41-ii42. | 0.6 | 1 |
| 117 | Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 446-454. | 3.3 | 75 |
| 118 | Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. <i>Cancer Research and Treatment</i> , 2019, 51, 502-509. | 1.3 | 74 |
| 119 | DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1640-1650. | 0.5 | 64 |
| 120 | Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. <i>Lung Cancer</i> , 2019, 135, 66-72. | 0.9 | 22 |
| 121 | Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722). <i>Annals of Oncology</i> , 2019, 30, vi126. | 0.6 | 7 |
| 122 | RELAY: Global Ph3 study of erlotinib + ramucirumab or placebo in metastatic NSCLC with EGFR mutation - East Asian subset. <i>Annals of Oncology</i> , 2019, 30, vi80. | 0.6 | 0 |
| 123 | Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-â€‘Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1608-1618. | 0.5 | 78 |
| 124 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669. | 5.1 | 418 |
| 125 | Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 12215. | 1.6 | 3 |
| 126 | Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74. | 1.3 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019, 10, 4278. | 5.8 | 263 |
| 128 | Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031. | 13.9 | 1,866 |
| 129 | Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery. <i>Radiotherapy and Oncology</i> , 2019, 133, 87-92. | 0.3 | 19 |
| 130 | Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. <i>Clinical Lung Cancer</i> , 2019, 20, e309-e316. | 1.1 | 11 |
| 131 | Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202. | 0.5 | 104 |
| 132 | Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. <i>Clinical Lung Cancer</i> , 2019, 20, 215-221. | 1.1 | 16 |
| 133 | Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 134, 7-15. | 0.9 | 38 |
| 134 | Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. , 2019, 7, 128. | | 27 |
| 135 | Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1255-1265. | 0.5 | 59 |
| 136 | First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the "real-world" clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983637. | 1.4 | 25 |
| 137 | Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1341-1349. | 1.2 | 19 |
| 138 | Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study. <i>Anticancer Research</i> , 2019, 39, 1403-1409. | 0.5 | 10 |
| 139 | Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2162-2170. | 0.8 | 202 |
| 140 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019, 133, 10-19. | 0.9 | 25 |
| 141 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131. | 0.9 | 26 |
| 142 | Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019, 130, 87-92. | 0.9 | 39 |
| 143 | Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439. | 2.3 | 26 |
| 144 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579. | 1.2 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383. | 1.1 | 10 |
| 146 | The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 1140-1150. | 0.0 | 0 |
| 147 | Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102. | 1.9 | 37 |
| 148 | In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing. <i>Journal of Thoracic Oncology</i> , 2019, 14, e279-e280. | 0.5 | 1 |
| 149 | Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0224379. | 1.1 | 12 |
| 150 | Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019, 128, 105-112. | 0.9 | 126 |
| 151 | Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non- ¹⁸ F-FDG Small-Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e60-e67. | 0.7 | 2 |
| 152 | The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2144-2154. | 3.2 | 134 |
| 153 | Abstract CT193: Tepotinib + gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study. , 2019, , . | | 2 |
| 154 | Abstract A138: CD39 increase on cytotoxic T-cell induced by myeloid-derived suppressor cell correlated with poor prognosis in patients with non-small cell lung cancer. <i>Cancer Immunology Research</i> , 2019, 7, A138-A138. | 1.6 | 2 |
| 155 | Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8514-8514. | 0.8 | 10 |
| 156 | Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8520-8520. | 0.8 | 4 |
| 157 | JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009. | 0.8 | 74 |
| 158 | Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9094-9094. | 0.8 | 1 |
| 159 | Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non- ¹⁸ F-FDG small-cell lung cancer (NSCLC): KEYNOTE-799.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8575-TPS8575. | 0.8 | 1 |
| 160 | Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 387-387. | 0.8 | 90 |
| 161 | Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1107-1115. | 0.7 | 1 |
| 162 | Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 119-127. | 1.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501. | 1.3 | 30 |
| 164 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222. | 1.3 | 12 |
| 165 | Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 408-412. | 1.3 | 15 |
| 166 | Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 623-631. | 1.3 | 40 |
| 167 | A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019, 51, 718-726. | 1.3 | 10 |
| 168 | Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 769-776. | 1.3 | 9 |
| 169 | Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2564-2564. | 0.8 | 0 |
| 170 | Abstract LB-297: Metabolic alterations in plasma associated with survival in small cell lung cancer. , 2019, , . | | 0 |
| 171 | Abstract 3137: DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in small cell lung cancer. , 2019, , . | | 0 |
| 172 | Abstract 143: Immune landscape in lung adenocarcinoma drawn by single-cell RNA sequencing. , 2019, , . | | 0 |
| 173 | Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. <i>Scientific Reports</i> , 2018, 8, 3284. | 1.6 | 20 |
| 174 | Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, e34-e36. | 0.5 | 28 |
| 175 | Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. <i>Lung Cancer</i> , 2018, 117, 7-13. | 0.9 | 12 |
| 176 | Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018, 118, 648-653. | 2.9 | 31 |
| 177 | Phase 1b Trial of Ficlatusumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 532-542. | 0.8 | 17 |
| 178 | Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584. | 0.5 | 62 |
| 179 | KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e29-e31. | 0.5 | 30 |
| 180 | Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 106-111. | 0.5 | 203 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. <i>Lung Cancer</i> , 2018, 119, 36-41. | 0.9 | 7 |
| 182 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479. | 1.1 | 56 |
| 183 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536. | 5.1 | 486 |
| 184 | A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 27-34. | 1.1 | 21 |
| 185 | Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6. | | 0 |
| 186 | Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. <i>Oncoimmunology</i> , 2018, 7, e1375642. | 2.1 | 83 |
| 187 | Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and Tj ETQq1 1 0.784314 rgBT /Overloc | 0.9 | 26 |
| 188 | Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. <i>Radiation Oncology</i> , 2018, 13, 245. | 1.2 | 3 |
| 189 | Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1468-1479. | 5.1 | 370 |
| 190 | Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. <i>Lung Cancer</i> , 2018, 126, 1-8. | 0.9 | 40 |
| 191 | Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1906-1918. | 0.5 | 88 |
| 192 | Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1156-1170. | 0.5 | 195 |
| 193 | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 122, 234-242. | 0.9 | 22 |
| 194 | Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. <i>PLoS ONE</i> , 2018, 13, e0194730. | 1.1 | 18 |
| 195 | Low-power and low-drug-dose photodynamic chemotherapy via the breakdown of tumor-targeted micelles by reactive oxygen species. <i>Journal of Controlled Release</i> , 2018, 286, 240-253. | 4.8 | 16 |
| 196 | Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. <i>Lung Cancer</i> , 2018, 124, 293-297. | 0.9 | 12 |
| 197 | Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164. | 0.9 | 10 |
| 198 | Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382. | 0.5 | 77 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1106-1112. | 0.5 | 42 |
| 200 | Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018, 109, 2852-2862. | 1.7 | 15 |
| 201 | A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102. | 0.8 | 87 |
| 202 | A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9025-9025. | 0.8 | 23 |
| 203 | Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9048-9048. | 0.8 | 3 |
| 204 | An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9050-9050. | 0.8 | 15 |
| 205 | Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9053-9053. | 0.8 | 4 |
| 206 | Durvalumab in 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9058-9058. | 0.8 | 3 |
| 207 | Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9075-9075. | 0.8 | 19 |
| 208 | An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3120-TPS3120. | 0.8 | 6 |
| 209 | Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 148-156. | 0.4 | 15 |
| 210 | Abstract B183: The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase Ib study. , 2018, , . | | 1 |
| 211 | Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21136-e21136. | 0.8 | 0 |
| 212 | Monitoring peripheral blood PD-1+CD8+T cells to predict response to anti-PD-1 therapy in solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24115-e24115. | 0.8 | 0 |
| 213 | Integrative whole-genome analysis of salivary duct carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6083-6083. | 0.8 | 0 |
| 214 | Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). <i>Cancer</i> , 2017, 123, 1958-1964. | 2.0 | 44 |
| 215 | Osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 225-231. | 0.9 | 4 |
| 216 | EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 465-469. | 1.0 | 156 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Characteristics and outcomes of <i>ALK</i> + non-small cell lung cancer patients in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e239-e245. | 0.7 | 6 |
| 218 | Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 126-133. | 0.9 | 11 |
| 219 | P3.02b-005 Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1187-S1188. | 0.5 | 2 |
| 220 | P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1214. | 0.5 | 1 |
| 221 | Prospects and progress of atezolizumab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 781-789. | 1.4 | 13 |
| 222 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet</i> , The, 2017, 389, 255-265. | 6.3 | 3,872 |
| 223 | A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 217-223. | 0.3 | 0 |
| 224 | Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2017, 61, 70-81. | 3.4 | 62 |
| 225 | An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 933-942. | 1.5 | 5 |
| 226 | ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1357-1367. | 0.5 | 144 |
| 227 | Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 591-598. | 1.1 | 47 |
| 228 | Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?. <i>Current Opinion in Oncology</i> , 2017, 29, 89-96. | 1.1 | 13 |
| 229 | Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2017, 117, 757-766. | 2.9 | 24 |
| 230 | Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377. | 5.8 | 137 |
| 231 | Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1806-1813. | 0.5 | 36 |
| 232 | Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 906-914. | 1.3 | 19 |
| 233 | Lipiodol nanoemulsions stabilized with polyglycerol-polycaprolactone block copolymers for theranostic applications. <i>Biomaterials Research</i> , 2017, 21, 21. | 3.2 | 10 |
| 234 | Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 3065-3074. | 0.8 | 349 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3662-3670. | 0.8 | 29 |
| 236 | Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-“Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15. | 1.5 | 31 |
| 237 | A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8521-8521. | 0.8 | 19 |
| 238 | Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8547-8547. | 0.8 | 1 |
| 239 | Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9001-9001. | 0.8 | 16 |
| 240 | Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. <i>Oncotarget</i> , 2017, 8, 3542-3552. | 0.8 | 7 |
| 241 | The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245. | 0.8 | 20 |
| 242 | Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center-“s experiences. <i>Oncotarget</i> , 2017, 8, 42478-42486. | 0.8 | 32 |
| 243 | Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i> -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 67526-67537. | 0.8 | 28 |
| 244 | NTRK gene amplification in patients with metastatic cancer. <i>Precision and Future Medicine</i> , 2017, 1, 129-137. | 0.5 | 20 |
| 245 | A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs.) Tj ETQq1 1 0.784314 rgBT /Overlook Research and Treatment, 2017, 49, 816-823. | 1.3 | 11 |
| 246 | Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. <i>Cancer Research and Treatment</i> , 2017, 49, 937-946. | 1.3 | 7 |
| 247 | Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. <i>Journal of Clinical Oncology</i> , 2017, 35, 92-92. | 0.8 | 0 |
| 248 | The feasibility of using small biopsy samples from lung cancer for targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20584-e20584. | 0.8 | 1 |
| 249 | Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience. <i>Cancer Research and Treatment</i> , 2017, 49, 880-889. | 1.3 | 2 |
| 250 | Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). <i>Oncotarget</i> , 2016, 7, 6984-6993. | 0.8 | 134 |
| 251 | The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016, 8, 3175-3186. | 0.6 | 4 |
| 252 | The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 14803-14813. | 0.8 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016, 122, 3024-3031. | 2.0 | 72 |
| 254 | Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy. <i>Head and Neck</i> , 2016, 38, E293-9. | 0.9 | 3 |
| 255 | Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients. <i>Scientific Reports</i> , 2016, 6, 37392. | 1.6 | 27 |
| 256 | Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2051-2052. | 0.5 | 6 |
| 257 | Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase II study. <i>Journal of Thoracic Oncology</i> , 2016, 11, S16. | 0.5 | 2 |
| 258 | Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. <i>Lung Cancer</i> , 2016, 96, 48-51. | 0.9 | 4 |
| 259 | AZD9291 overcomes T790M-mediated resistance through degradation of EGFR L858R/T790M in non-small cell lung cancer cells. <i>Investigational New Drugs</i> , 2016, 34, 407-415. | 1.2 | 13 |
| 260 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589. | 5.1 | 950 |
| 261 | Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. <i>Lung Cancer</i> , 2016, 96, 56-62. | 0.9 | 39 |
| 262 | A Randomized Phase 2 Study Comparing the Combination of Ficlatazumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1736-1744. | 0.5 | 46 |
| 263 | Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2202-2207. | 0.5 | 3 |
| 264 | Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer. <i>World Neurosurgery</i> , 2016, 95, 399-405. | 0.7 | 6 |
| 265 | LUX-Lung 7: is there enough data for a final conclusion? " Author's reply. <i>Lancet Oncology</i> , The, 2016, 17, e268-e269. | 5.1 | 0 |
| 266 | Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. <i>Medical Oncology</i> , 2016, 33, 97. | 1.2 | 39 |
| 267 | Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. <i>Lung Cancer</i> , 2016, 100, 24-29. | 0.9 | 5 |
| 268 | MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3. <i>Journal of Thoracic Oncology</i> , 2016, 11, S256. | 0.5 | 12 |
| 269 | Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. <i>Lung Cancer</i> , 2016, 98, 9-14. | 0.9 | 25 |
| 270 | Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. <i>Cancer Imaging</i> , 2016, 16, 5. | 1.2 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. <i>Investigational New Drugs</i> , 2016, 34, 625-635. | 1.2 | 52 |
| 272 | Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, e1-e4. | 0.5 | 76 |
| 273 | Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. <i>Lung Cancer</i> , 2016, 93, 95-103. | 0.9 | 41 |
| 274 | Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e45-e47. | 0.5 | 98 |
| 275 | Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 397-406. | 1.4 | 56 |
| 276 | Reply to Y.H. Kim and M. Mishima. <i>Journal of Clinical Oncology</i> , 2016, 34, 768-768. | 0.8 | 0 |
| 277 | Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 40-45. | 0.6 | 9 |
| 278 | First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 370-379. | 0.5 | 21 |
| 279 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474. | 0.5 | 156 |
| 280 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1837-1846. | 6.3 | 2,390 |
| 281 | First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 305. | 3.4 | 201 |
| 282 | Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). <i>Clinical Cancer Research</i> , 2016, 22, 2386-2395. | 3.2 | 169 |
| 283 | Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). <i>Radiotherapy and Oncology</i> , 2016, 118, 244-250. | 0.3 | 43 |
| 284 | A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2016, 22, 2139-2145. | 3.2 | 30 |
| 285 | Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. <i>Supportive Care in Cancer</i> , 2016, 24, 301-309. | 1.0 | 11 |
| 286 | Highly dense, optically inactive silica microbeads for the isolation and identification of circulating tumor cells. <i>Biomaterials</i> , 2016, 75, 271-278. | 5.7 | 31 |
| 287 | Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)., 2016, , . | | 1 |
| 288 | Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial—A feasibility analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11534-11534. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. Journal of Clinical Oncology, 2016, 34, 2508-2508. | 0.8 | 21 |
| 290 | Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 6090-6090. | 0.8 | 3 |
| 291 | A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. Journal of Clinical Oncology, 2016, 34, 9013-9013. | 0.8 | 16 |
| 292 | Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. Journal of Clinical Oncology, 2016, 34, 9028-9028. | 0.8 | 16 |
| 293 | Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.. Journal of Clinical Oncology, 2016, 34, 9032-9032. | 0.8 | 14 |
| 294 | A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.. Journal of Clinical Oncology, 2016, 34, 9043-9043. | 0.8 | 1 |
| 295 | First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology, 2016, 34, 9046-9046. | 0.8 | 11 |
| 296 | BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. Journal of Clinical Oncology, 2016, 34, 9055-9055. | 0.8 | 27 |
| 297 | A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET) Tj ETQq1 1 0.784314 r3BT /Ove | 0.8 | 14 |
| 298 | Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. Journal of Clinical Oncology, 2016, 34, e20501-e20501. | 0.8 | 6 |
| 299 | First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS2597-TPS2597. | 0.8 | 4 |
| 300 | Integrated genomic approaches identify upregulation of <i>SCRN1</i> as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget, 2016, 7, 13797-13809. | 0.8 | 7 |
| 301 | Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget, 2016, 7, 36311-36320. | 0.8 | 44 |
| 302 | Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study. Annals of Translational Medicine, 2016, 4, 476-476. | 0.7 | 3 |
| 303 | Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. Journal of Pathology and Translational Medicine, 2016, 50, 258-263. | 0.4 | 50 |
| 304 | Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A & Post Hoc& Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. Cancer Research and Treatment, 2016, 48, 458-464. | 1.3 | 1 |
| 305 | Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. Cancer Research and Treatment, 2016, 48, 527-536. | 1.3 | 104 |
| 306 | East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). Cancer Research and Treatment, 2016, 48, 1177-1186. | 1.3 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e14118-e14118. | 0.8 | 0 |
| 308 | Pattern and dynamics of recurrence after induction chemoradiotherapy (CCRT) followed by surgery (Trimodality Treatment) in stage IIIA(N2) NSCLC: The impact of response to preoperative CCRT on recurrence.. Journal of Clinical Oncology, 2016, 34, e20030-e20030. | 0.8 | 0 |
| 309 | Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.. Journal of Clinical Oncology, 2016, 34, e20520-e20520. | 0.8 | 0 |
| 310 | Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH). , 2016, , . | | 0 |
| 311 | Abstract 2931: Integrated genomic approaches identify upregulation of SCRNI as a novel mechanism associated with acquired resistance to erlotinib in non small cell lung cancer cells with oncogenic EGFR mutation. , 2016, , . | | 0 |
| 312 | Abstract 2837: The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. , 2016, , . | | 0 |
| 313 | Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFR^{mut}) NSCLC: LUX-Lung 7. , 2016, , . | | 0 |
| 314 | The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2015, 10, 903-909. | 0.5 | 36 |
| 315 | The MISSION Impossible? No, the Journey Should Continue with Better Targeting!. Journal of Thoracic Oncology, 2015, 10, 1667-1669. | 0.5 | 0 |
| 316 | Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget, 2015, 6, 40360-40369. | 0.8 | 85 |
| 317 | Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS Genetics, 2015, 11, e1005467. | 1.5 | 104 |
| 318 | Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget, 2015, 6, 28211-28222. | 0.8 | 57 |
| 319 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 763-774. | 5.1 | 431 |
| 320 | Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery. Cancer Chemotherapy and Pharmacology, 2015, 75, 77-85. | 1.1 | 14 |
| 321 | A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. Cancer Chemotherapy and Pharmacology, 2015, 75, 1229-1236. | 1.1 | 7 |
| 322 | A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2015, 10, 1800-1806. | 0.5 | 28 |
| 323 | Tumor-Targeted Delivery of Paclitaxel Using Low Density Lipoprotein-Mimetic Solid Lipid Nanoparticles. Molecular Pharmaceutics, 2015, 12, 1230-1241. | 2.3 | 47 |
| 324 | Imaging: Low-Density Lipoprotein-Mimicking Nanoparticles for Tumor-Targeted Theranostic Applications (Small 2/2015). Small, 2015, 11, 146-146. | 5.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. <i>Lung Cancer</i> , 2015, 87, 148-154. | 0.9 | 81 |
| 326 | BYL719, a selective inhibitor of phosphoinositide 3-Kinase $\hat{\pm}$, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 12-21. | 1.2 | 24 |
| 327 | Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2450-2456. | 0.8 | 61 |
| 328 | Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Lung Cancer</i> , 2015, 16, 228-236. | 1.1 | 23 |
| 329 | Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients. <i>Pharmacogenomics</i> , 2015, 16, 383-391. | 0.6 | 8 |
| 330 | EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey. <i>Journal of Thoracic Oncology</i> , 2015, 10, 438-445. | 0.5 | 156 |
| 331 | Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 331-337. | 0.5 | 163 |
| 332 | Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015, 33, 2660-2666. | 0.8 | 215 |
| 333 | Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015, 90, 261-266. | 0.9 | 4 |
| 334 | Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2015, 125, 331-338. | 1.4 | 20 |
| 335 | Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series. <i>Head and Neck</i> , 2015, 37, E66-E69. | 0.9 | 10 |
| 336 | Low-Density Lipoprotein-Mimicking Nanoparticles for Tumor-Targeted Theranostic Applications. <i>Small</i> , 2015, 11, 222-231. | 5.2 | 25 |
| 337 | Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8010-8010. | 0.8 | 77 |
| 338 | A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8041-8041. | 0.8 | 1 |
| 339 | Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8084-8084. | 0.8 | 28 |
| 340 | A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8086-8086. | 0.8 | 1 |
| 341 | The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid) Tj ETQq1 1 e12540-e12540. | 0.8 | 1 |
| 342 | The prevalence and prognostic relevance of PD-L1 expression in patients with HPV-negative and HPV-positive oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14003-e14003. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 30929-30938. | 0.8 | 10 |
| 344 | The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368. | 0.8 | 24 |
| 345 | NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035. | 0.8 | 53 |
| 346 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 44971-44984. | 0.8 | 13 |
| 347 | Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy. <i>Clinical and Experimental Otorhinolaryngology</i> , 2015, 8, 142. | 1.1 | 25 |
| 348 | The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 88. | 0.7 | 12 |
| 349 | Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy. <i>Cancer Research and Treatment</i> , 2015, 47, 871-878. | 1.3 | 19 |
| 350 | Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 645-652. | 1.3 | 7 |
| 351 | Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22241-e22241. | 0.8 | 0 |
| 352 | Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8078-8078. | 0.8 | 3 |
| 353 | Abstract 3897: High-throughput profiling of actionable mutations in salivary duct carcinoma. , 2015, , . | | 0 |
| 354 | Alk Translocation in Sarcomatoid Carcinoma of Head and Neck and Treatment Effect of Crizotinib: a Case Series. <i>Annals of Oncology</i> , 2014, 25, v76. | 0.6 | 0 |
| 355 | Concurrent Chemoradiation with Three Weekly Versus Weekly Cisplatin in Locally Advanced Nasopharyngeal Cancer Patients. <i>Annals of Oncology</i> , 2014, 25, v76. | 0.6 | 0 |
| 356 | High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. <i>Journal of Translational Medicine</i> , 2014, 12, 299. | 1.8 | 41 |
| 357 | Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. <i>Oncologist</i> , 2014, 19, 702-703. | 1.9 | 11 |
| 358 | Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2059-2066. | 0.8 | 127 |
| 359 | Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1523-1531. | 0.5 | 19 |
| 360 | Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21. <i>Journal of Thoracic Oncology</i> , 2014, 9, 506-511. | 0.5 | 44 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 259-264. | 0.9 | 30 |
| 362 | Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 50-58. | 3.3 | 116 |
| 363 | Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 2083-2090. | 0.7 | 24 |
| 364 | Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 121-128. | 0.8 | 176 |
| 365 | Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 1254-1262. | 5.1 | 95 |
| 366 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014, 50, 2219-2230. | 1.3 | 44 |
| 367 | Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1063-1070. | 1.1 | 18 |
| 368 | Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1217-1225. | 1.1 | 32 |
| 369 | Prognostic value of volumetric metabolic parameters measured by [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. <i>Cancer Imaging</i> , 2014, 14, 2. | 1.2 | 24 |
| 370 | A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin. <i>Lung Cancer</i> , 2014, 84, 51-55. | 0.9 | 28 |
| 371 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet</i> , The, 2014, 384, 665-673. | 6.3 | 1,068 |
| 372 | Abstract 1526: Integrative and comparative genomic analysis of East-Asian lung squamous cell carcinomas. , 2014, , . | | 2 |
| 373 | A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CChelN).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7500-7500. | 0.8 | 5 |
| 374 | A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8008-8008. | 0.8 | 25 |
| 375 | Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8011-8011. | 0.8 | 39 |
| 376 | Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/ gefitinib (E/G) and afatinib's LUX-Lung 5 (LL5).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8019-8019. | 0.8 | 21 |
| 377 | Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8044-8044. | 0.8 | 9 |
| 378 | A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8051-8051. | 0.8 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 379 | REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.. Journal of Clinical Oncology, 2014, 32, LBA8006-LBA8006. | 0.8 | 6 |
| 380 | Abstract A02: Targeted deep sequencing of second biopsy tissues from patients with acquired resistance (AR) to EGFR tyrosine kinase inhibitors harboring EGFR mutations: Preliminary results.. Clinical Cancer Research, 2014, 20, A02-A02. | 3.2 | 0 |
| 381 | Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET+), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm+) and progression on gefitinib.. Journal of Clinical Oncology, 2014, 32, TPS8121-TPS8121. | 0.8 | 0 |
| 382 | The presence of ALK translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series.. Journal of Clinical Oncology, 2014, 32, e17048-e17048. | 0.8 | 0 |
| 383 | Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).. Journal of Clinical Oncology, 2014, 32, 6023-6023. | 0.8 | 0 |
| 384 | A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.. Journal of Clinical Oncology, 2014, 32, 4083-4083. | 0.8 | 0 |
| 385 | Randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8037-8037. | 0.8 | 0 |
| 386 | Abstract 4453: Synergistic anticancer effect of combination of AZD6244 and BYL719 targeting KRAS mutant in non-small cell lung cancer. , 2014, , . | | 0 |
| 387 | Abstract 5587: Serial monitoring ofEGFRmutations in plasma and evaluation ofEGFRmutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. , 2014, , . | | 0 |
| 388 | Prognostic value of ¹⁸ Fâ€FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volumeâ€based metabolic parameters. Head and Neck, 2013, 35, 15-22. | 0.9 | 111 |
| 389 | Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute. Medical Oncology, 2013, 30, 479. | 1.2 | 19 |
| 390 | Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1005-1013. | 3.3 | 53 |
| 391 | Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer, 2013, 79, 300-306. | 0.9 | 22 |
| 392 | The Effect of N/P Ratio on the In Vitro and In Vivo Interaction Properties of PEGylated Poly[2-(dimethylamino)ethyl methacrylate]-based siRNA Complexes. Macromolecular Bioscience, 2013, 13, 1059-1071. | 2.1 | 58 |
| 393 | Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer. Journal of Molecular Diagnostics, 2013, 15, 51-61. | 1.2 | 63 |
| 394 | Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer, 2013, 79, 40-45. | 0.9 | 32 |
| 395 | Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system. Lung Cancer, 2013, 81, 65-70. | 0.9 | 19 |
| 396 | Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer, 2013, 82, 294-298. | 0.9 | 101 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. <i>Lung Cancer</i> , 2013, 82, 455-460. | 0.9 | 30 |
| 398 | The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 231-235. | 0.9 | 16 |
| 399 | Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons. <i>Biosensors and Bioelectronics</i> , 2013, 46, 142-149. | 5.3 | 14 |
| 400 | Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. <i>Genomics</i> , 2013, 102, 157-162. | 1.3 | 42 |
| 401 | A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib. <i>Journal of Thoracic Oncology</i> , 2013, 8, e91-e92. | 0.5 | 5 |
| 402 | Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 250-253. | 0.5 | 43 |
| 403 | Ethnic differences in non-small-cell lung cancer treatment: the Asian perspective. <i>Lung Cancer Management</i> , 2013, 2, 309-315. | 1.5 | 2 |
| 404 | Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 185-191. | 0.5 | 163 |
| 405 | A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 959-966. | 0.5 | 36 |
| 406 | Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. <i>Molecular Cancer Therapeutics</i> , 2013, 12, B25-B25. | 1.9 | 5 |
| 407 | Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/II trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 8027-8027. | 0.8 | 22 |
| 408 | Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/II trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 8028-8028. | 0.8 | 28 |
| 409 | Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e64816. | 1.1 | 71 |
| 410 | Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma. <i>Cancer Research and Treatment</i> , 2013, 45, 343-348. | 1.3 | 6 |
| 411 | Abstract 3493: A single-tube, multiplexed, transcript-based assay to detect ALK, ROS1 and RET fusions in lung cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3493-3493. | | 0 |
| 412 | Roles of cMET/ErbB3 activation and overexpression in the development of resistance to EGFR inhibitors in NSCLC patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 11113-11113. | 0.8 | 0 |
| 413 | Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, e19051-e19051. | 0.8 | 0 |
| 414 | High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients. <i>Anticancer Research</i> , 2013, 33, 5127-33. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan- α -Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3337-3344. | 0.8 | 247 |
| 416 | Repeat Biopsy for Mutational Analysis of Non-Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications. <i>Radiology</i> , 2012, 265, 939-948. | 3.6 | 98 |
| 417 | The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S8001. | 0.6 | 1 |
| 418 | A Dramatic Response to Crizotinib in a Non-Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e36-e38. | 0.5 | 87 |
| 419 | Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 315-320. | 1.1 | 17 |
| 420 | The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 784-791. | 1.9 | 159 |
| 421 | EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. <i>Lancet Oncology</i> , 2012, 13, 33-42. | 5.1 | 526 |
| 422 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology</i> , 2012, 13, 528-538. | 5.1 | 904 |
| 423 | Baseline SUVmax at PET-CT in Stage IIIA Non-small-cell Lung Cancer Patients Undergoing Surgery after Neoadjuvant Therapy. <i>Academic Radiology</i> , 2012, 19, 440-445. | 1.3 | 14 |
| 424 | Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR). <i>Journal of Clinical Oncology</i> , 2012, 30, 1114-1121. | 0.8 | 233 |
| 425 | International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1. <i>Journal of Clinical Oncology</i> , 2012, 30, 2829-2836. | 0.8 | 179 |
| 426 | A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01). <i>European Journal of Cancer</i> , 2012, 48, 3198-3204. | 1.3 | 26 |
| 427 | Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. <i>Lung Cancer</i> , 2012, 75, 82-88. | 0.9 | 94 |
| 428 | ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. <i>Lung Cancer</i> , 2012, 76, 253-254. | 0.9 | 26 |
| 429 | Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study. <i>Lung Cancer</i> , 2012, 77, 339-345. | 0.9 | 34 |
| 430 | Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer?. <i>Lung Cancer</i> , 2012, 77, 365-370. | 0.9 | 130 |
| 431 | First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung. <i>Journal of Clinical Oncology</i> , 2012, 30, 1122-1128. | 0.8 | 694 |
| 432 | High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2012, 53, 1120. | 0.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?. Korean Journal of Radiology, 2012, 13, 702. | 1.5 | 57 |
| 434 | Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG01). Cancer, 2012, 118, 6234-6242. | 2.0 | 89 |
| 435 | Reappraisal of <i>KIT</i> mutation in adenoid cystic carcinomas of the salivary gland. Journal of Oral Pathology and Medicine, 2012, 41, 415-423. | 1.4 | 7 |
| 436 | Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Investigational New Drugs, 2012, 30, 368-375. | 1.2 | 17 |
| 437 | The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Human Genetics, 2012, 131, 365-372. | 1.8 | 45 |
| 438 | Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): Asian subgroup analysis.. Journal of Clinical Oncology, 2012, 30, 7549-7549. | 0.8 | 1 |
| 439 | Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy.. Journal of Clinical Oncology, 2012, 30, 7557-7557. | 0.8 | 14 |
| 440 | EGFR status and daily dose: Effect on tumor growth inhibition in cancer patients treated with dacomitinib (PF-00299804).. Journal of Clinical Oncology, 2012, 30, e18093-e18093. | 0.8 | 4 |
| 441 | ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (<i>EGFR</i>) mutation-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, TPS7614-TPS7614. | 0.8 | 13 |
| 442 | High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histology and Histopathology, 2012, 27, 197-207. | 0.5 | 130 |
| 443 | Abstract 1718: Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer patients were associated with low expression of thymidylate synthase in tumor. , 2012, , . | | 0 |
| 444 | A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 7104-7104. | 0.8 | 0 |
| 445 | Metabolic response evaluated by 18F-FDG PET/CT as a potential tool in identifying subgroup of patients with advanced non-small cell lung cancer for immediate maintenance treatment after first-line chemotherapy.. Journal of Clinical Oncology, 2012, 30, e18148-e18148. | 0.8 | 0 |
| 446 | Comparison of clinical outcomes between concurrent chemoradiotherapy followed by adjuvant chemotherapy and concurrent chemoradiotherapy alone for patients associated with locally advanced nasopharyngeal carcinoma: A retrospective analysis of single center experience.. Journal of Clinical Oncology, 2012, 30, e16003-e16003. | 0.8 | 1 |
| 447 | Influence of Nano-Carrier Architecture on <i>in Vitro</i> siRNA Delivery Performance and <i>in Vivo</i> Biodistribution: Polyplexes vs Micelleplexes. ACS Nano, 2011, 5, 3493-3505. | 7.3 | 109 |
| 448 | Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer, 2011, 71, 89-93. | 0.9 | 83 |
| 449 | New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer, 2011, 73, 63-69. | 0.9 | 55 |
| 450 | INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer, 2011, 11, 430. | 1.1 | 74 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron Emission Tomography and Computed Tomography. <i>Journal of Thoracic Oncology</i> , 2011, 6, 336-342. | 0.5 | 23 |
| 452 | Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1392-1399. | 0.5 | 108 |
| 453 | Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2011, 47, 714-719. | 0.8 | 17 |
| 454 | Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. <i>Supportive Care in Cancer</i> , 2011, 19, 491-495. | 1.0 | 40 |
| 455 | The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 687-694. | 1.2 | 34 |
| 456 | Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1203-1211. | 1.2 | 43 |
| 457 | Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 531-538. | 1.1 | 20 |
| 458 | Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1099-1109. | 1.1 | 86 |
| 459 | Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR tyrosine kinase inhibitors. <i>Cancer</i> , 2011, 117, 143-151. | 2.0 | 31 |
| 460 | Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 655-660. | 0.4 | 35 |
| 461 | Dry Pleural Dissemination in Non-Small Cell Lung Cancer: Prognostic and Diagnostic Implications. <i>Radiology</i> , 2011, 260, 568-574. | 3.6 | 25 |
| 462 | A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer. <i>Oncology</i> , 2011, 80, 175-180. | 0.9 | 30 |
| 463 | Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naïve patients with extensive-disease small cell lung cancer. <i>Cancer</i> , 2010, 116, 132-136. | 2.0 | 17 |
| 464 | Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2010, 5, 688-695. | 0.5 | 45 |
| 465 | Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1185-1196. | 0.5 | 52 |
| 466 | Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance Therapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, 540-545. | 0.5 | 30 |
| 467 | Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 369-375. | 0.5 | 38 |
| 468 | Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1609-1615. | 0.5 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 469 | Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA). <i>Medical Oncology</i> , 2010, 27, 1234-1238. | 1.2 | 20 |
| 470 | Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. <i>Cancer</i> , 2010, 116, 676-685. | 2.0 | 32 |
| 471 | Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. <i>Cancer</i> , 2010, 116, 3025-3033. | 2.0 | 34 |
| 472 | Involved-Lesion Radiation Therapy After Chemotherapy in Limited-Stage Head-and-Neck Diffuse Large B Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 507-512. | 0.4 | 20 |
| 473 | Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria. <i>Korean Journal of Radiology</i> , 2010, 11, 618. | 1.5 | 23 |
| 474 | Lung Cancer Working Group Report. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i7-i12. | 0.6 | 17 |
| 475 | Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. <i>Oncology</i> , 2010, 79, 78-84. | 0.9 | 14 |
| 476 | Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?. <i>Lung Cancer</i> , 2010, 68, 258-263. | 0.9 | 26 |
| 477 | A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 420-426. | 0.9 | 55 |
| 478 | Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2010, 69, 105-109. | 0.9 | 21 |
| 479 | Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy. <i>Lung Cancer</i> , 2010, 69, 330-336. | 0.9 | 80 |
| 480 | The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, 323-329. | 0.9 | 60 |
| 481 | Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: An observation for more than 10 years. <i>Lung Cancer</i> , 2010, 69, 123-126. | 0.9 | 69 |
| 482 | Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 644-652. | 1.2 | 14 |
| 483 | Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 1307-1314. | 3.2 | 173 |
| 484 | Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras. <i>Oncology</i> , 2009, 76, 239-246. | 0.9 | 18 |
| 485 | Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5861-5868. | 3.2 | 191 |
| 486 | Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. <i>International Journal of Cancer</i> , 2009, 124, 1457-1462. | 2.3 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 487 | Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. <i>Cancer</i> , 2009, 115, 1518-1530. | 2.0 | 20 |
| 488 | Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 89-97. | 1.1 | 35 |
| 489 | The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. <i>Medical Oncology</i> , 2009, 26, 287-291. | 1.2 | 56 |
| 490 | Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". <i>Annals of Hematology</i> , 2009, 88, 111-119. | 0.8 | 32 |
| 491 | Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 917-924. | 1.1 | 5 |
| 492 | Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray. <i>Proteomics</i> , 2009, 9, 5544-5552. | 1.3 | 20 |
| 493 | L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large cell neuroendocrine tumors. <i>Apmis</i> , 2009, 117, 140-146. | 0.9 | 14 |
| 494 | Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. <i>Apmis</i> , 2009, 117, 861-869. | 0.9 | 16 |
| 495 | Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study. <i>European Journal of Cancer</i> , 2009, 45, 2298-2303. | 1.3 | 47 |
| 496 | Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial. <i>Lung Cancer</i> , 2009, 66, 338-343. | 0.9 | 16 |
| 497 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. <i>Lancet</i> , The, 2009, 373, 1525-1531. | 6.3 | 1,321 |
| 498 | Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 809-815. | 0.5 | 145 |
| 499 | Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1136-1143. | 0.5 | 25 |
| 500 | Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model. <i>Cancer Research and Treatment</i> , 2009, 41, 80. | 1.3 | 3 |
| 501 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. <i>Investigational New Drugs</i> , 2008, 26, 387-392. | 1.2 | 19 |
| 502 | A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 77-84. | 1.1 | 38 |
| 503 | Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008, 25, 447-450. | 1.2 | 7 |
| 504 | ERCC1 expression as a prognostic marker in N2(+) nonsmall cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. <i>Cancer</i> , 2008, 113, 1379-1386. | 2.0 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 505 | Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3543-3551. | 0.8 | 3,032 |
| 506 | Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?. <i>Clinical Cancer Research</i> , 2008, 14, 3860-3866. | 3.2 | 52 |
| 507 | Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 88-94. | 0.6 | 21 |
| 508 | FDG PET/CT and Mediastinal Nodal Metastasis Detection in Stage T1 Non-Small Cell Lung Cancer: Prognostic Implications. <i>Korean Journal of Radiology</i> , 2008, 9, 481. | 1.5 | 12 |
| 509 | Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type. <i>Clinical Cancer Research</i> , 2007, 13, 3250-3254. | 3.2 | 48 |
| 510 | Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5233-5239. | 0.8 | 175 |
| 511 | Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 716-722. | 0.6 | 33 |
| 512 | P2-328: Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S851. | 0.5 | 85 |
| 513 | PD3-2-2: Changing the natural history of advanced non-small cell lung cancer with gefitinib? A single-center experience in Korea. <i>Journal of Thoracic Oncology</i> , 2007, 2, S462-S463. | 0.5 | 0 |
| 514 | PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S464-S465. | 0.5 | 1 |
| 515 | Clinical evaluation of incadronate in Korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. <i>Current Therapeutic Research</i> , 2007, 68, 193-204. | 0.5 | 1 |
| 516 | Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. <i>Cancer Letters</i> , 2007, 258, 90-97. | 3.2 | 19 |
| 517 | Paclitaxel with Cisplatin as Salvage Treatment for Patients with Previously Treated Advanced Transitional Cell Carcinoma of the Urothelial Tract. <i>Neoplasia</i> , 2007, 9, 18-22. | 2.3 | 32 |
| 518 | The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 972-978. | 0.6 | 283 |
| 519 | Postremission therapy for acute myeloid leukemia in the first remission. <i>Leukemia and Lymphoma</i> , 2007, 48, 937-943. | 0.6 | 6 |
| 520 | Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 55, 329-336. | 0.9 | 19 |
| 521 | Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. <i>Lung Cancer</i> , 2007, 58, 116-122. | 0.9 | 21 |
| 522 | PD2-2-3: Prognostic significance of L1 cell adhesion molecule (CAM) expression in pulmonary neuroendocrine tumors. <i>Journal of Thoracic Oncology</i> , 2007, 2, S440. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 523 | PD4-1-4: A phase III randomized trial with or without Consolidation Chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in Inoperable stage III Non-small cell lung cancer (CCheIN): Preliminary report for feasibility and safety. <i>Journal of Thoracic Oncology</i> , 2007, 2, S448-S449. | 0.5 | 0 |
| 524 | Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. <i>American Journal of Hematology</i> , 2007, 82, 446-452. | 2.0 | 41 |
| 525 | Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. <i>Cancer</i> , 2007, 109, 1561-1569. | 2.0 | 120 |
| 526 | Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. <i>Biomaterials</i> , 2007, 28, 5555-5561. | 5.7 | 87 |
| 527 | Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007, 31, 359-364. | 0.4 | 41 |
| 528 | What is stage II in high-grade primary gastric lymphoma?. <i>Leukemia Research</i> , 2007, 31, 1039-1043. | 0.4 | 2 |
| 529 | Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. <i>Clinical Immunology</i> , 2007, 125, 257-267. | 1.4 | 64 |
| 530 | A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 489-494. | 1.1 | 18 |
| 531 | C3-06: ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small cell lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery. <i>Journal of Thoracic Oncology</i> , 2007, 2, S367. | 0.5 | 3 |
| 532 | PD6-2-7: A single institutional experience of thymic epithelial tumors over 11 years: clinical features and outcome and implications for future management. <i>Journal of Thoracic Oncology</i> , 2007, 2, S430-S431. | 0.5 | 0 |
| 533 | D3-07: SNP of Phospholipase D1 gene as a Predictive Marker for Response to Chemotherapy in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S399. | 0.5 | 0 |
| 534 | High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population. <i>Leukemia and Lymphoma</i> , 2006, 47, 2128-2131. | 0.6 | 14 |
| 535 | Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. <i>Lung Cancer</i> , 2006, 52, 75-81. | 0.9 | 11 |
| 536 | Is trimodality approach better than bimodality in stage IIIA, N2 positive non-small cell lung cancer?. <i>Lung Cancer</i> , 2006, 53, 323-330. | 0.9 | 22 |
| 537 | Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 612-618. | 0.8 | 560 |
| 538 | A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small cell lung cancer. <i>Current Medical Research and Opinion</i> , 2006, 22, 561-573. | 0.9 | 85 |
| 539 | Pulmonary Complications After Hematopoietic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2006, 21, 406. | 1.1 | 29 |
| 540 | Prognosis of Non-Small Cell Lung Cancer with Synchronous Brain Metastases Treated with Gamma Knife Radiosurgery. <i>Journal of Korean Medical Science</i> , 2006, 21, 527. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 541 | Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome. <i>Leukemia Research</i> , 2006, 30, 1253-1258. | 0.4 | 10 |
| 542 | Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. <i>Annals of Hematology</i> , 2006, 85, 285-290. | 0.8 | 19 |
| 543 | Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. <i>Annals of Hematology</i> , 2006, 85, 781-786. | 0.8 | 43 |
| 544 | Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 17-21. | 1.1 | 21 |
| 545 | Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma. <i>European Journal of Haematology</i> , 2006, 77, 304-308. | 1.1 | 10 |
| 546 | Isolated Blast Crisis in CNS in a Patient With Chronic Myelogenous Leukemia Maintaining Major Cytogenetic Response After Imatinib. <i>Journal of Clinical Oncology</i> , 2006, 24, 4028-4029. | 0.8 | 23 |
| 547 | CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1253-1259. | 0.6 | 18 |
| 548 | Preoperative Concurrent Radiochemotherapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer. <i>Journal of Korean Medical Science</i> , 2006, 21, 229. | 1.1 | 4 |
| 549 | Mouse Orthotopic Lung Cancer Model Induced by PC14PE6. <i>Cancer Research and Treatment</i> , 2006, 38, 234. | 1.3 | 18 |
| 550 | Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. <i>International Journal of Hematology</i> , 2005, 81, 258-263. | 0.7 | 6 |
| 551 | Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. <i>European Journal of Cancer</i> , 2005, 41, 1402-1408. | 1.3 | 152 |
| 552 | Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma. <i>Annals of Thoracic Surgery</i> , 2005, 80, 1170-1175. | 0.7 | 59 |
| 553 | Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 1491-1491. | 0.6 | 0 |
| 554 | Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment. <i>Leukemia and Lymphoma</i> , 2004, 45, 339-344. | 0.6 | 50 |
| 555 | Primary Pulmonary Non-Hodgkin's Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 510-514. | 0.6 | 103 |
| 556 | Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4383-4388. | 3.2 | 74 |
| 557 | Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 477-480. | 0.6 | 41 |
| 558 | A Randomized Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir Therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 3162-3162. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 559 | A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer, 2003, 42, 227-235. | 0.9 | 20 |
| 560 | Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2002, 52, 75-80. | 0.4 | 41 |
| 561 | Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Investigational New Drugs, 2001, 19, 81-83. | 1.2 | 123 |
| 562 | Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study. Human Gene Therapy, 2001, 12, 671-684. | 1.4 | 123 |
| 563 | Mechanistic Aspects of Green Tea as a Cancer Preventive: Effect of Components on Human Stomach Cancer Cell Lines. Japanese Journal of Cancer Research, 1999, 90, 733-739. | 1.7 | 132 |
| 564 | Fractionated stereotactic radiation therapy for locally recurrent nasopharynx cancer: Report of three cases. , 1999, 21, 338-345. | | 13 |
| 565 | Real-time automatically updated data warehouse in healthcare (ROOT: An Innovative and Automated) Tj ETQq1 1 0.784314 JgBT /Over 1.3 | | |